FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (BeyondSpring or the Company), a clinical-stage global biopharmaceutical company focused on developing...
- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and...
FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (BeyondSpring or the Company), a clinical-stage global biopharmaceutical company focused on developing...
FLORHAM PARK, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (œBeyondSpring or the œCompany), a global clinical-stage biopharmaceutical company focused on using a...
NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (œBeyondSpring or the œCompany), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
NEW YORK, Dec. 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (BeyondSpring or the Company), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
New Clinical Data from MD Anderson Presented at the Society for Immunotherapy of Cancer™s 38th Annual Meeting80% DCR (disease control rate) in non-radiated tumor with Durable Responses in Heavily...
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (œBeyondSpring or the œCompany), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering œmolecular glues and harnessing its targeted protein degradation...